Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | ACE | P12821 | 1/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.73 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.73 |
| ▸ | PDE4A | P27815 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390517 | 1.00 | PPARG (0.73) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL7309057 | 0.95 | PPARG (0.66) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL7304123 | 0.93 | PPARG (0.68) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL3679091 | 0.93 | PPARG (0.65) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL7309650 | 0.92 | PPARG (0.67) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL12463072 | 0.92 | PPARG (0.72) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL2040839 | 0.91 | PPARG (0.67) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL9094539 | 0.90 | PPARG (0.77) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL8268211 | 0.90 | PPARG (0.80) | PPARGKDM4EABCC3ABCC4USP2 | |
| SCHEMBL12664495 | 0.88 | PPARG (0.77) | PPARGKDM4EABCC3ABCC4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264491-A1 | Telmisartan production process | CHEMAGIS LTD. (IL) | 2006-11-23 | — | — | US | claimed |
| CN-110836943-B | Analysis method for impurity detection of telmisartan tablets and telmisartan capsules | 江西杏林白马药业股份有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-107966519-B | High performance liquid chromatography analysis method and detection method of impurities in telmisartan | 威特(湖南)药业有限公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-110836943-A | Analysis method for impurity detection of telmisartan tablets and telmisartan capsules | 江西杏林白马药业有限公司 | 2020-02-25 | — | — | CN | disclosed |
| US-9499491-B2 | One pot process for the preparation of telmisartan | AMARNATH U (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9499491-B2 | One pot process for the preparation of telmisartan | AMARNATH U (IN) | 2016-11-22 | — | — | US | disclosed |
| US-20150197495-A1 | ONE POT PROCESS FOR THE PREPARATION OF TELMISARTAN | AMARNATH U (IN) | 2015-07-16 | — | — | US | disclosed |
| US-20150197495-A1 | ONE POT PROCESS FOR THE PREPARATION OF TELMISARTAN | AMARNATH U (IN) | 2015-07-16 | — | — | US | disclosed |
| US-8993778-B2 | Process for manufacture of telmisartan | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-8993778-B2 | Process for manufacture of telmisartan | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-20060264491-A1 | Telmisartan production process | CHEMAGIS LTD. (IL) | 2006-11-23 | — | — | US | disclosed |
| WO-2004087676-A1 | METHOD FOR THE PRODUCTION OF TELMISARTAN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-14 | — | — | WO | disclosed |
| EP-0502314-B1 | Benzimidazol derivatives, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1998-05-20 | — | — | EP | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5565469-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1996-10-15 | — | — | US | disclosed |
| EP-0682021-A1 | Benzimidazoles, medicines containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1995-11-15 | — | — | EP | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264491-A1 | Telmisartan production process | AGT, REN, ACE | PPARG 2049/4885KDM4E 2878/4885ABCC3 4708/4885 |
| US-20150197495-A1 | ONE POT PROCESS FOR THE PREPARATION OF TELMISARTAN | REN, AGTR1, AGT | PPARG 3482/4885KDM4E 388/4885ABCC3 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.